News and Insights

The latest news and insights from Genoa Healthcare.

  • Clinical Insights

February 2024 drug trend report

Staying on top of new drug launches and shortages can be difficult. Read Genoa Healthcare’s latest drug trend report for an overview and connect with your local pharmacy team to...

  • Feb 1st, 2024
  • Clinical Insights

Uzedy™: Long-acting injection for the treatment of schizophrenia

Learn more about this new treatment option for adults living with schizophrenia Genoa is here to help keep you informed on the latest in behavioral health medications. Read on to...

  • Jan 31st, 2024
  • Clinical Insights

Brixadi®: 3 things to know about the buprenorphine treatment option

Staying on top of new medication therapy options for your consumers living with opioid use disorder (OUD) can be difficult. Learn how the new FDA-approved medication, Brixadi®, can help support...

  • Dec 6th, 2023
  • Clinical Insights

November 2023 drug trend report

Staying on top of new drug launches and shortages can be difficult. Read Genoa Healthcare’s latest drug trend report for an overview of the latest and connect with your local...

  • Nov 1st, 2023
  • Clinical Insights

September 2023 drug trend report

Genoa Healthcare’s latest drug trend report highlights information on new medication launches as well as noteworthy drug shortages currently in market. Brand name drug launches* Brixadi™ Zurzuvae™ (zuranolone) Generic drug...

  • Sep 1st, 2023
  • Clinical Insights

Caring for those with treatment-resistant depression

Genoa Healthcare® can partner with you to improve outcomes for your patients living with TRD. Connect with us to get started today. One in three adults with major depressive disorder...

  • Aug 9th, 2023
  • Clinical Insights

4 things to know about Spravato® (Intranasal esketamine)

Looking for information on Spravato®? Here are four things you should know. Spravato®: What, why and how? Spravato® is an FDA-approved nasal spray indicated for the treatment of treatment-resistant depression...

  • Aug 9th, 2023
  • Clinical Insights

August 2023 drug trend report

Genoa Healthcare’s latest drug trend report highlights information on new medication launches as well as noteworthy drug shortages currently in market. Brand name drug launches* Uzedy Abilify Asimtuffii Brixadi Generic...

  • Aug 2nd, 2023
  • Clinical Insights

Currently available and emerging therapy options for treatment-resistant depression

Studies show that 50% of people with major depressive disorder don’t respond adequately to initial antidepressant treatment.1 Additionally, an estimated 30% of people with major depressive disorder (MDD) experience treatment-resistant...

  • Aug 2nd, 2023
  • Clinical Insights

Frequently asked questions: naloxone (Narcan®)

Narcan® information and sources were taken from www.narcan.com. 1. FDA Approves First Over-the-Counter Naloxone Nasal Spray. 3/29/2023. FDA Approves First Over-the-Counter Naloxone Nasal Spray | FDA

  • Mar 29th, 2023